On August 22, 2025, Liminatus Pharma, Inc. received a notice from Nasdaq for not meeting their filing requirements due to a delay in submitting its Quarterly Report for the period ended June 30, 2025. The company has until October 21, 2025, to present a compliance plan to avoid potential delisting.